RayThera, Inc. raised $110 million in Series A financing. The funding will advance their preclinical immunology pipeline and was co-led by Foresite Capital and OrbiMed Advisors.
RayThera, Inc. raised $110 million in Series A financing. The funding will advance their preclinical immunology pipeline and was co-led by Foresite Capital and OrbiMed Advisors.
04/04/25, 5:12 PM
Location
san diegoMoney raised
$110 million
Industry
pharmaceutical
biotechnology
Round Type
series a
Investors
Ttm Capital, Orbi Med Advisors, Foresite Capital
RayThera, Inc., a recently founded biotechnology company focused on small molecule therapies in immunology, has completed its Series A financing with a total of $110 million raised. The financing was co-led by Foresite Capital and OrbiMed Advisors, with participation from TTM Capital. Proceeds will be used to advance RayThera’s lead drug candidates through Phase 1 clinical studies. The strong support from investors is instrumental for the company’s growth.
Company Info
Location
san diego, california, united states
Additional Info
RayThera, Inc. is a small molecule drug discovery company focused on building an immunology pipeline. The company is led by a team of highly skilled drug hunters with extensive experience in the biotech and pharma industries. Their aim is to discover and develop small molecule therapies in immunology. RayThera is dedicated to advancing its lead drug candidates through clinical studies.